Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons
Diabetes · 2025
DOI: 10.2337/db23-1025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2025. Verfasst von Muhammad Saad Yousuf und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Pain Studies, Department of Neuroscience, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Pyruvaldehyde, Ganglia, Spinal, Fumarates. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NINDS NIH HHS, NSERC Postdoctoral Fellowship.
Abstract (Originalsprache)
Diabetic neuropathic pain is associated with elevated plasma levels of methylglyoxal (MGO). MGO is a metabolite of glycolysis that causes pain hypersensitivity in mice by stimulating the phosphorylation of eukaryotic initiation factor 2α (p-eIF2α) and subsequently activating the integrated stress response (ISR). We first established that Zucker Diabetic Fatty (ZDF) rats have enhanced MGO signaling, engage the ISR, and develop pain hypersensitivity. Since nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of antioxidant proteins that neutralize MGO, we hypothesized that fumarates, like diroximel fumarate (DRF), will stimulate Nrf2 signaling, and prevent MGO-induced ISR and pain hypersensitivity. DRF (100 mg/kg) treated animals were protected from developing MGO (20 ng) induced mechanical and cold hypersensitivity. Mechanistically, DRF treatment protected against MGO-induced increase in p-eIF2α levels in the sciatic nerve and reduced loss of intraepidermal nerve fiber (IENF) density. Using Nrf2-knockout mice we demonstrate that Nrf2 is necessary for the anti-nociceptive effects of DRF. Co-treatment of MGO (1µM) with monomethyl fumarate (MMF) (10, 20, 50 µM), the active metabolite of DRF, prevented the ISR in both mouse and human DRG neurons. Our data show that targeting Nrf2 with DRF is a strategy to potentially alleviate pain associated with elevated MGO levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Advanced Pain Studies, Department of Neuroscience, School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX.
- Department of Molecular and Translational Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Science Center El Paso, El Paso, TX.
- Laboratories of Neuroimmunology, Department of Symptom Research, University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Muhammad Saad Yousuf
Förderung
- NIDDK NIH HHS
- NINDS NIH HHS
- NSERC Postdoctoral Fellowship
- NIH HHS
Zitieren
APA
Yousuf, M. S., Mancilla Moreno, M., Woodall, B. J., Thakur, V., Li, J., He, L., Arjarapu, R., Royer, D., Zhang, J., Chattopadhyay, M., Grace, P. M., & Price, T. J. (2025). Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons. Diabetes. https://doi.org/10.2337/db23-1025
Vancouver
Yousuf MS, Mancilla Moreno M, Woodall BJ, Thakur V, Li J, He L, et al. Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons. Diabetes. 2025. doi:10.2337/db23-1025
BibTeX
@article{Yousuf2025,
author = {Yousuf, Muhammad Saad and Mancilla Moreno, Marisol and Woodall, Brodie J and Thakur, Vikram and Li, Jiahe and He, Lucy and Arjarapu, Rohita and Royer, Danielle and Zhang, Jennifer and Chattopadhyay, Munmun and Grace, Peter M and Price, Theodore J},
title = {Diroximel fumarate acts through Nrf2 to attenuate methylglyoxal-induced nociception in mice and decrease ISR activation in DRG neurons},
journal = {Diabetes},
year = {2025},
doi = {10.2337/db23-1025}
}
EUVIMED